Nan Zhou

Nan Zhou

Auto-generated profile, based on publicly available information

Nan Zhou

Institute of Human Virology, Department of Pathogen Biology and Biosecurity, and Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China; Center for Infection and Immunity Study, Zhongshan School of Medicine, Sun Yat-sen University, Shenzhen 518107, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2021 in Nature
Verified
Journal Article
Closed access
PDF file
DSDaniele Simoneschi
Daniele Simoneschi
GRGergely Róna
Gergely Róna
NZNan Zhou
Nan Zhou
YJYeon-Tae Jeong
Yeon-Tae Jeong
SJShaowen Jiang
Shaowen Jiang
MPMichele Pagano
Michele Pagano

15 June 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
RSRizwan Saffie
Rizwan Saffie
NZNan Zhou
Nan Zhou
DRDelphine Rolland
Delphine Rolland
ÖÖÖzlem Önder
Özlem Önder
VBVenkatesha Basrur
Venkatesha Basrur
LBLuca Busino
Luca Busino
Mature B-cell neoplasms are the fifth most common neoplasm. Due to significant heterogeneity at the clinical and genetic levels, current therapies for these cancers fail to provide long-term cures. The clinical success of proteasome inhibition for the treatment of multiple myeloma and B-cell lymphomas has made the ubiquitin pathway an important emerging therapeutic target. In this study, we assessed the role of the E3 ligase FBXW7 in mature B-cell neoplasms. FBXW7 targeted the frequently inactivated tumor suppressor KMT2D for protein degradation, subsequently regulating gene expression signatures related to oxidative phosphorylation (OxPhos). Loss of FBXW7 inhibited diffuse large B-cell lymphoma cell growth and further sensitized cells to OxPhos inhibition. These data elucidate a novel mechanism of regulation of KMT2D levels by the ubiquitin pathway and uncover a role of FBXW7 in regulating oxidative phosphorylation in B-cell malignancies. Significance: These findings characterize FBXW7 as a prosurvival factor in B-cell lymphoma via degradation of the chromatin modifier KMT2D.

14 September 2023 in Blood
Verified
Journal Article
Open access
PDF file
NZNan Zhou
Nan Zhou
JCJaewoo Choi
Jaewoo Choi
GGGrant Peter Grothusen
Grant Peter Grothusen
BKBang-Jin Kim
Bang-Jin Kim
DRDiqiu Ren
Diqiu Ren
LBLuca Busino
Luca Busino
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Up to 40% of patients with DLBCL display refractory disease or relapse after standard chemotherapy treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]), leading to significant morbidity and mortality. The molecular mechanisms of chemoresistance in DLBCL remain incompletely understood. Using a cullin–really interesting new gene (RING) ligase-based CRISPR-Cas9 library, we identify that inactivation of the E3 ubiquitin ligase KLHL6 promotes DLBCL chemoresistance. Furthermore, proteomic approaches helped identify KLHL6 as a novel master regulator of plasma membrane–associated NOTCH2 via proteasome-dependent degradation. In CHOP-resistant DLBCL tumors, mutations of NOTCH2 result in a protein that escapes the mechanism of ubiquitin-dependent proteolysis, leading to protein stabilization and activation of the oncogenic RAS signaling pathway. Targeting CHOP-resistant DLBCL tumors with the phase 3 clinical trial molecules nirogacestat, a selective γ-secretase inhibitor, and ipatasertib, a pan-AKT inhibitor, synergistically promotes DLBCL destruction. These findings establish the rationale for therapeutic strategies aimed at targeting the oncogenic pathway activated in KLHL6- or NOTCH2-mutated DLBCL.

28 September 2023 in Blood
Verified
Journal Article
Open access
PDF file
NZNan Zhou
Nan Zhou
LBLuca Busino
Luca Busino
In this issue of Blood, Schmitt et al1 have identified the bromodomain-containing 4 (BRD4) protein as a suppressor of ferroptosis in diffuse large B-cell lympho

31 March 2023
Verified
Other
Open access
RSRizwan Saffie
Rizwan Saffie
NZNan Zhou
Nan Zhou
DRDelphine Rolland
Delphine Rolland
ÖÖÖzlem Önder
Özlem Önder
VBVenkatesha Basrur
Venkatesha Basrur
LBLuca Busino
Luca Busino
Supplementary Data (Fig. S1- S6)

31 March 2023
Verified
Other
Open access
RSRizwan Saffie
Rizwan Saffie
NZNan Zhou
Nan Zhou
DRDelphine Rolland
Delphine Rolland
ÖÖÖzlem Önder
Özlem Önder
VBVenkatesha Basrur
Venkatesha Basrur
LBLuca Busino
Luca Busino
Supplementary Data (Fig. S1- S6)